Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxybutynin
Drug ID BADD_D01643
Description Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]
Indications and Usage For the treatment of overactive bladder.
Marketing Status Prescription; OTC; Discontinued
ATC Code G04BD04
DrugBank ID DB01062
KEGG ID D00465
MeSH ID C005419
PubChem ID 4634
TTD Drug ID D0R1DH
NDC Product Code 68382-257; 50090-5352; 0615-8220; 70771-1088; 70771-1086; 68382-255; 0023-6153; 71335-0974; 68382-256; 70771-1087; 50090-5353; 0615-8219; 17381-015; 0023-9637
Synonyms oxybutynin | 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate | 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate | Zatur | Contimin | Cystonorm | Ditropan | Dridase | Cystrin | Dresplan | Driptane | gelnique | Gen-Oxybutynin | Novo-Oxybutynin | Nu-Oxybutyn | Oxyb AbZ | Oxybutin Holsten | Oxybuton | Oxybutynin AL | Oxybutynin AZU | Oxybutynin Heumann | Oxybutynin Hexal | oxybutynin hydrochloride | oxybutynin chloride | Oxybutynin Stada | oxybutynin von ct | Oxybutynin-Puren | Oxybutynin-ratiopharm | Oxymedin | Oxytrol | PMS-Oxybutynin | Pollakisu | Renamel | Ryol | Spasmex Oxybutynin | Spasyt | Tavor | Oxybugamma | Apo-Oxybutynin
Chemical Information
Molecular Formula C22H31NO3
CAS Registry Number 5633-20-5
SMILES CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Enuresis20.02.02.003; 19.07.04.0010.000262%Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.0010.000524%Not Available
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.007--
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Frequent bowel movements07.02.04.002--Not Available
Fungal infection11.03.05.001--Not Available
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.004--
Glaucoma06.03.01.002--
Glossitis07.14.01.001--Not Available
Haematuria24.07.01.047; 20.02.01.006--
Hair disorder23.02.06.003--Not Available
Hallucination19.10.02.0020.000393%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages